Peter Llewellyn-Davies
Direktor/Vorstandsmitglied bei SHIELD THERAPEUTICS PLC
Vermögen: 3 006 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Hans-Peter Hasler | M | 68 | 6 Jahre | |
Hansjörg Plaggemars | M | 53 | 5 Jahre | |
Jackie Mitchell | M | - | 12 Jahre | |
Christian Schweiger | M | 57 | 16 Jahre | |
Dolores Schendel | M | - | 10 Jahre | |
Alexander Link | M | 53 | 4 Jahre | |
David Childs | M | - | 13 Jahre | |
Gregory Madison | M | 57 | 3 Jahre | |
Andreas Pahl | M | - | 12 Jahre | |
Karl Lundström | M | 62 | 3 Jahre | |
Lucy Huntington-Bailey | F | - | 9 Jahre | |
Christof Hettich | M | 64 | 14 Jahre | |
Maria Lacerca-Allen | M | 57 | 3 Jahre | |
Paul Spoors | M | - | 5 Jahre | |
Karen Chandler Smith | F | - | - | |
Edward Charles | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 4 Jahre |
Andreas Gerber | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 Jahre |
Erwin Rasinger | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Helmut Schühsler | M | 65 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Rainer Herschlein | M | - | 3 Jahre | |
Andy Hurley | M | - | 1 Jahre | |
Eva Katheder | F | - | 3 Jahre | |
Manfred Reichl | M | 71 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 17 Jahre |
Birgit Kudlek | M | 57 | 12 Jahre | |
Ulrich Granzer | M | 63 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 Jahre |
Santosh Shanbhag | M | 47 | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Tim Watts | M | 66 | 3 Jahre | |
Richard Jones | M | 58 | 7 Jahre | |
Carl Sterritt | M | 55 | 12 Jahre | |
Joanne Elizabeth Estell | F | 53 | - | |
Angela Hildreth | F | - | 6 Jahre | |
James Karis | M | 76 | 4 Jahre | |
María del Pilar de la Huerta Martínez | F | 55 | 8 Jahre | |
Charlotte Lohmann | F | 54 | 11 Jahre | |
David Lemus | M | 61 | 1 Jahre | |
Markus Dangl | M | - | - | |
Jan Schmidt-Brand | M | - | 12 Jahre | |
Heikki Lanckriet | M | 46 | 4 Jahre | |
Frank Mathias | M | 62 | 13 Jahre | |
Josef Penninger | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 16 Jahre |
Joseph Fernández | M | 64 | 9 Jahre | |
Rolf K. Hoffmann | M | 64 | 3 Jahre | |
Karl Keegan | M | 57 | 1 Jahre | |
Andrew Heath | M | 76 | 2 Jahre | |
Thomas Werner | M | 68 | 3 Jahre | |
Mark Sampson | M | - | 5 Jahre | |
Paul Steckler | M | - | - | |
Rainer C. Burian | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
Jose Menoyo | M | - | 2 Jahre | |
Iris Löw-Friedrich | M | 63 | - | |
Mathias Albert Boehringer | M | - | 5 Jahre | |
Tim McCarthy McCarthy | M | 68 | 4 Jahre | |
Norbert Riedel | M | 66 | 10 Jahre | |
David Ebsworth | M | 69 | - | |
David John Roth | M | 56 | 3 Jahre | |
Pol Bamelis | M | 85 | 12 Jahre | |
Thomas Borcholte | M | - | 6 Jahre | |
Alexandra Goll | M | 68 | 6 Jahre | |
Olav Zilian | M | - | 1 Jahre | |
Trevor Jarman | M | 76 | 4 Jahre | |
Klaus Kühn | M | 72 | 2 Jahre | |
Kai Pinkernell | M | - | - | |
Rudiger Hauffe | M | - | - | |
Yi Ta Li | M | - | - | |
Cristina Garmendia Mendizábal | M | - | 7 Jahre | |
Andreas Krebs | M | 65 | 6 Jahre | |
Martin Bürmann | M | 55 | - | |
Hans-Peter Rudolf | M | 58 | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 35 | 51,47% |
Vereinigtes Königreich | 25 | 36,76% |
Österreich | 8 | 11,76% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Peter Llewellyn-Davies
- Persönliches Netzwerk